Presentation, patterns of care, and outcomes of patients with prostate cancer in sub‐Saharan Africa: A population‐based registry study. Issue 22 (30th July 2021)

• Record Type: Journal Article
• Authors: Seraphin, Tobias Paul; Joko‐Fru, Walburga Yvonne; Hämmerl, Lucia; Griesel, Mirko; Mezger, Nikolaus Christian Simon; Feuchtner, Jana Cathrin; Adoubi, Innocent; Egué, Marcel Dieu‐Donné; Okerosi, Nathan; Wabinga, Henry; Hansen, Rolf; Vuma, Samukeliso; Lorenzoni, Cesaltina; Coulibaly, Bourama; Odzebe, Sévérin W.; Buziba, Nathan Gyabi; Aynalem, Abreha; Liu, Biying; Medenwald, Daniel; Mikolajczyk, Rafael T.; Efstathiou, Jason Alexander; Parkin, Donald Maxwell; Jemal, Ahmedin; Kantelhardt, Eva Johanna
• Is Part Of: Cancer. Volume 127:Issue 22(2021)
• Page Start: 4221
• Page End: 4232
• Publication Date: 2021-07-30
• Subjects: Africa -- population‐based cancer registration -- prostate cancer -- staging -- survival -- treatment; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.33818
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Background: Although prostate cancer (PCa) is the most commonly diagnosed cancer in men of sub‐Saharan Africa (SSA), little is known about its management and survival. The objective of the current study was to describe the presentation, patterns of diagnosis, treatment, and survival of patients with PCa in 10 countries of SSA. Methods: In this observational registry study with data collection from 2010 to 2018, the authors drew a random sample of 738 patients with PCa who were registered in 11 population‐based cancer registries. They described proportions of patients receiving recommended care and presented survival estimates. Multivariable Cox regression was used to calculate hazard ratios comparing the survival of patients with and without cancer‐directed therapies (CDTs). Results: The study included 693 patients, and tumor characteristics and treatment information were available for 365 patients, 37.3% of whom had metastatic disease. Only 11.2% had a complete diagnostic workup for risk stratification. Among the nonmetastatic patients, 17.5% received curative‐intent therapy, and 27.5% received no CDT. Among the metastatic patients, 59.6% received androgen deprivation therapy. The 3‐ and 5‐year age‐standardized relative survival for 491 patients with survival time information was 58.8% (95% confidence interval [CI], 48.5%‐67.7%) and 56.9% (95% CI, 39.8%‐70.9%), respectively. In a multivariable analysis, survival was considerably poorer among patients without CDT versus those with therapy. Conclusions: This study shows that a large proportion of patients with PCa in SSA are not staged or are insufficiently staged and undertreated, and this results in unfavorable survival. These findings reemphasize the need for improving diagnostic workup and access to care in SSA in order to mitigate the heavy burden of the disease in the region. Abstract : Patients in sub‐Saharan Africa are inadequately staged and undertreated and suffer from poor survival. Improving diagnostic services and access to therapy could improve survival for African patients with prostate cancer.